A recent head-to-head trial SURMOUNT-5, published in N Engl J Med, found that tirzepatide produced larger mean weight loss than semaglutide at the primary time point (tirzepatide 20.2% vs semaglutide 13.7%)
The latter is consistent with our own findings of increased GSH concentrations in treated hypertensive patients (9)
State-licensed pharmacies operating under Section 503A had until February 18, 2025, to wind down production
Benefits at a glance: Tirzepatide/Cyanocobalamin - Effective in reducing HbA1c levels, a measure of long-term blood sugar control - Promotes significant weight loss, which is beneficial for individuals with obesity or overweight - Improves insulin sensitivity, leading to better glycemic control - Reduces the risk of cardiovascular events, such as heart attacks or strokes - Convenient once-weekly dosing, providing convenience and adherence to treatment - Demonstrates superior glycemic control compared to other diabetes medications, ensuring better blood sugar management - Well-tolerated with manageable side effects, enhancing patient compliance and satisfaction - Shows promise in reducing liver fat and improving liver health, which can have significant implications for individuals with fatty liver disease or non-alcoholic steatohepatitis (NASH).
Wegovy Dosing and Treatment in Riverview All Riverview patients begin their Wegovy journey with a lower dosage for four weeks, increasing as tolerated under careful supervision
